FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lefebvre, M
   Vignier, N
   Pitard, B
   Botelho-Nevers, E
   Wyplosz, B
   Cohen, R
   Epaulard, O
AF Lefebvre, M.
   Vignier, N.
   Pitard, B.
   Botelho-Nevers, E.
   Wyplosz, B.
   Cohen, R.
   Epaulard, O.
CA SPILF Vaccination Prevention Grp
TI COVID-19 vaccines: Frequently asked questions and updated answers
SO INFECTIOUS DISEASES NOW
LA English
DT Review
AB At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named COVID-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective antiviral treatment, and mass vaccination came to be considered as the strategy most likely to put an end to the pandemic. The objective of this text is to address and hopefully answer the questions being put forward by healthcare professionals on the different anti-SARS-CoV-2 vaccines as regards their development, their modes of action, their effectiveness, their limits, and their utilization in different situations; we are proposing a report on both today's state of knowledge, and the 14 February 2021 recommendations of the French health authorities.
C1 [Lefebvre, M.] Univ Hotel Dieu, Ctr Hosp, Ctr Prevent Malad Infect & Transmissibles, Serv Malad Infect & Trop,Inserm CIC1413, 1 Pl Alexis Ricordeau, F-44000 Nantes, France.
   [Vignier, N.] Ctr Hosp Andree Rosemon, Ctr Invest Clin Antilles Guyane, CIC Inserm 1424, DRISP, Cayenne, French Guiana.
   [Vignier, N.] Sorbonne Univ, INSERM, IPLESP, Inst Pierre Louis Epidemiol & Sante Publ, F-75012 Paris, France.
   [Pitard, B.] Univ Nantes, CNRS ERL6001, Inserm 1232, CRCINA, Nantes, France.
   [Botelho-Nevers, E.] Univ St Etienne, Ctr Hosp, Serv Infectiol, CIC 1408 Inserm, F-42055 St Etienne, France.
   [Botelho-Nevers, E.] Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol CIRI, Univ Jean Monnet, Univ Lyon,Team GIMAP,INSERM U1111,CNRS,UMR530, F-42023 St Etienne, France.
   [Cohen, R.] Ctr Hosp Intercommunal Creteil, Serv Pediat, InfoVac, 40 Ave Verdun, F-94000 Creteil, France.
   [Epaulard, O.] Univ Grenoble Alpes, Ctr Hosp, Serv Malad Infect, Grenoble, France.
   [Epaulard, O.] CIC 1406 Inserm, Grenoble, France.
   [Vignier, N.] Grp Hosp Sud Ile De France, Dept Infect Dis, F-77000 Melun, France.
   [Wyplosz, B.] Ctr Hosp Univ Bicetre, AP HP, Serv Malad Infect & Trop, Paris, France.
RP Lefebvre, M (corresponding author), Univ Hotel Dieu, Ctr Hosp, Ctr Prevent Malad Infect & Transmissibles, Serv Malad Infect & Trop,Inserm CIC1413, 1 Pl Alexis Ricordeau, F-44000 Nantes, France.
EM naeva.lefebvre@chu-nantes.fr
RI Cohen, Robert/AAM-4426-2021; Vignier, Nicolas/AAH-8382-2021; Epaulard,
   Olivier/AHD-4798-2022
OI Cohen, Robert/0000-0001-6151-0686; Vignier, Nicolas/0000-0002-9410-9327;
   
CR Abu Jabal K, 2021, IMPACT ETHNICITY SEX
   Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), 2021, POINT SIT SURV VACC
   Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM) Agence nationale de securite du medicament et des produits de sante (ANSM), 2021, AV ANSM CONC 2 DOS V
   Aley PK, 2021, SAFETY EFFICACY CHAD, V397, P99
   American College of Obstetricians and Gynecologists (ACOG), 2020, VACC PREGN LACT PAT
   Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436
   Bhosle SM, 2018, BIOMATERIALS, V1
   Bhosle SM, 2011, NUCLEIC ACIDS RES, V39, P1595
   Blanchard EL, 2019, MOL THER-NUCL ACIDS, V14, P52, DOI 10.1016/j.omtn.2018.11.002
   Breathnach AS, 2021, J INFECTION, V82, pE11, DOI 10.1016/j.jinf.2021.01.005
   CDC, 2021, INT CLIN CONS US MRN
   CDC,, 2021, VACC CONS PEOPL WHO
   Centre de Reference sur les Agents Teratogenes (CRAT) Centre de Reference sur les Agents Teratogenes (CRAT), 2021, CACC ARNM COV 19 GRO
   Chodick G., 2021, EFFECTIVENESS 1 DOSE, DOI [10.1101/2021.01.27.21250612, DOI 10.1101/2021.01.27.21250612]
   Claro I.M., 2021, GENOMIC CHARACTERISA
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063
   De Befardinrs P, 2020, FRONT IMMUNOL, P21
   Du L., 2020, INFECT DIS THER, V9, P1
   Ebrallifill M, 2019, DAIRY VET SCI J, V11
   Essink, 2021, NEW ENGL J MED, V184, P401
   EVANS DIK, 1990, BRIT MED J, V300, P1694, DOI 10.1136/bmj.300.6741.1694-a
   Fang Wang, 2019, JCI INSIGHT, V1, pE123
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5
   Giegoio E, 2021, P NATL ACAD SCI USA, V1
   Halstead SR, ANTIBODY DEPENDENT E
   Hanrath AT, 2020, J INFECT, DOI [10.1016/ijin12020.12.023, DOI 10.1016/IJIN12020.12.023]
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2020, STRATEGIC VACCINATIO
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2021, STRAT VACC SARS COV
   Haute Autorite de sante (HAS) Haute Autorite de sante (HAS) Haute Autorite de sante (HAS) Haute Autorite de sante (HAS), 2021, MOD SCHEM VACC SARS
   Herzog C, 2014, EXPERT REV VACCINES, V13, P399, DOI 10.1586/14760584.2014.883285
   Institut national du cancer (InCA), 2021, PREC PRIOR PAT ATT C
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Johnson WE, 2015, REV VIROL, V2
   Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]
   ladlock TA, ETIOK GY DR RGNOSFS, VI, P93
   LauElIsangHuiKwanChanChiu, 2021, NAT COMMUN, V12, P6
   Lemarchand M, 2020, IND PHARM
   Lemarchand M, 2021, IND PHARM
   Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8
   Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3
   Long Quan-Xin, 2020, Nature Medicine, V26, DOI 10.1038/s41591-020-0965-6
   Longini Pet OV, AD HOCEXPEII GUMP NE
   Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545
   Ma ttachatsa S, 2010, J ADV PHARM TECHNOL, V1, P11
   Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n124
   MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749
   Martiny A-kin BD, 1993, EURJ IMMUNOL VACCINE, V21, P19
   Medicines and Healthcare Products Regulatory Agency Medicines and Healthcare Products Regulatory Agency, 2020, U ASTRAZENECA COV 19
   Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante Ministere des Solidarites et de la Sante, 2021, INT OL VER DEL VACC
   Msomi N., 2020, MEDRXIV, DOI 10.1101/2020.12.21.20248640
   Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Munn I, TRENDS BIOTECHNOL, V2, P94
   Nokleby H, 2006, CURR ALLERGY ASTHM R, V6, P9, DOI 10.1007/s11882-006-0003-x
   Pauli N, NIT REV DRUG LISCOV, V17, P261
   Planning VII, 2020, VACCINES VACCINE, V18, P6191
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Poletto, 2020, EVALUATION STRATEGIE
   Qiu Y, 2010, SCAND J IMMUNOL, V72, P425, DOI 10.1111/j.1365-3083.2010.02456.x
   Rambaut A., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.17.046086, 10.1101/2020.04.17.046086]
   ridhar ti, N ENGL MED
   RiN P, 2017, J ALLERGY CLIN IMMUN, V16, P811
   Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341
   Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5
   Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967
   Societe francaise d'allergologie (SFA) Societe francaise d'allergologie (SFA), 2021, VACC COVID 19
   Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR) Societe francaise de rhumatologie (SFR), 2021, VACC COVID 19 PAT AT
   SoniatChook MYM, 2015, BIOCHEMISTRY-US
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0
   Vogel AB., 2020, BIORXIV, DOI 10.1101/2020.09.08.280818.
   Voysey M, 2021, SINGLE DOSE ADM INFL
   Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906
   Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]
   Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195
   Woolsey C, 2021, NAT IMMUNOL, V22, P86, DOI 10.1038/s41590-020-00835-8
   World Health Organization, 2021, DRAFT LANDSC TRACK C
   World Health Organization (WHO) World Health Organization (WHO), 2021, BNT162B2 WHO
   Wu K, 2021, MRNA 1273 CACCINE IN, DOI 10,1101/2021,01.25.427948
NR 81
TC 4
Z9 4
U1 0
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2666-9927
EI 2666-9919
J9 INFECT DIS NOW
JI Infect. Dis. Now
PD JUN
PY 2021
VL 51
IS 4
BP 319
EP 333
DI 10.1016/j.idnow.2021.02.007
EA MAY 2021
PG 15
WC Infectious Diseases
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases
GA SE2AB
UT WOS:000651874700001
PM 33681861
OA Bronze, Green Published
DA 2022-05-16
ER

EF